Søren Lemonius

Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark.

Biomonitor ApS conducts research and development focusing on developing bioassays to monitor patients’ response to biological therapeutics. It offers services in the field of biopharmaceuticals, patient monitoring services through measurement of drug levels and immunogenicity of biopharmaceuticals in patients under therapy of these drugs, and customized reporter-gene cell-based assay development. The company was founded by Klaus Bendtzen and Arsalan Kharazmi on October 30, 2003 and is headquartered in Herlev, Denmark.

Chempaq was formed in 2001 by Ulrik Larsen who is the founder, based on Larsen idea to redefine the hematology test by creating a single use self contained cassette module. This PAQ (cassette) was designed to be easy to use automatically calibrated and to deliver high accuracy and precision. In February 2005, the Chempaq XBC was CE marked. Later in the same year in December, the Chempaq XBC received a 510(k) clearance from the FDA. Since 2005, Doctors offices and Hospitals have provided patients with a unique infection diagnosis using the Chempaq XBC product.

Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors.

ACE BioSciences A/S engages in the research and experimental development on biotechnology. It offers medical research, production, and sale of medical products. The company was founded on September 15, 2000 and is headquartered in Hillerød, Denmark.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

TD Vaccines A/S S is a holding company that focuses on the development of vaccines to protect against travellers' diarrhoea (TD). It is a biotechnology company that discovers and develops novel vaccines to fight serious bacterial infections. Its lead programme is ACE527, an oral ETEC vaccine to protect against ETEC (Enterotoxigenic E Coli). Its oral combination vaccine, ACE920, designs to protect against ETEC and Campylobacter infections. The company was founded in November 2009 and is headquartered in Skorping, Denmark.